|
04 Nov 2021 |
Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Tumor-targeted Immune Cell Agonist™ BT7480 in Patients with Advanced Solid Tumors Associated with Nectin-4 Expression
|
|
04 Nov 2021 |
Zealand Pharma Announces First Subject Dosed in Phase 1 Trial of Amylin Analogue ZP8396 for the Treatment of Obesity
|
|
04 Nov 2021 |
Codexis and Nestlé Health Science Initiate a Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency
|
|
04 Nov 2021 |
Molecular Partners Announces First Patient Dosed with CD40 Therapeutic Candidate MP0317 in Phase 1 Clinical Trial
|
|
01 Nov 2021 |
Viking Therapeutics Presents Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek® 2021
|
|
28 Oct 2021 |
Synthekine Advances IL-2 Partial Agonist, STK-012, into Clinical Investigation for Treatment of Solid Tumors
|
|
27 Oct 2021 |
Alkermes Initiates ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer
|
|
25 Oct 2021 |
MIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Complete Response Rate Using KRYSTEXXA® (pegloticase injection) with Methotrexate
|
|
25 Oct 2021 |
ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer
|
|
23 Oct 2021 |
Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Did Not Meet Primary Endpoint
|
|
21 Oct 2021 |
Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatase
|
|
18 Oct 2021 |
Radius Announces Positive Phase 3 Topline Results for TYMLOS® (abaloparatide) Subcutaneous Injection in Males with Osteoporosis
|
|
18 Oct 2021 |
Xilio Therapeutics Announces FDA Clearance of Investigational New Drug Application for XTX202 for the Treatment of Solid Tumors
|
|
14 Oct 2021 |
Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA)
|
|
12 Oct 2021 |
APEIRON Biologics commences clinical COVID-19 trial with inhaled APN01
|
|
09 Oct 2021 |
Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286
|
|
09 Oct 2021 |
Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial
|
|
30 Sep 2021 |
FDA grants Priority Review for investigational targeted radioligand therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC)
|
|
20 Sep 2021 |
Arecor announces positive headline results from first phase I clinical trial of AT278 ultra-concentrated ultra-rapid acting insulin candidate for diabetes
|
|
18 Sep 2021 |
Alpha Cancer Technologies Inc. Presents New Data from ACT-903, an AFP-maytansine Conjugate, at 2021 European Society of Medical Oncology Annual Meeting
|
|
15 Sep 2021 |
Medicenna Doses First Patient in MDNA11 Phase 1/2 ABILITY Study
|
|
11 Sep 2021 |
Amolyt Pharma Exercises Option to License Optimized Acromegaly Drug Candidate from PeptiDream as it Continues to Build its Rare Endocrine Pipeline
|
|
10 Sep 2021 |
Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022
|
|
09 Sep 2021 |
Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not on Prophylaxis
|
|
08 Sep 2021 |
AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan
|
